Skip to main content
SpringerLink
Log in

Treatment Algorithm for Polycythemia Vera

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 473 Accesses

Abstract

Polycythemia Vera (PV) is a myeloproliferative disease characterized by a high red blood cell mass. Patients often present with an elevated hemoglobin, though may have elevated platelets and white blood cells as well. The majority of the patients who have this disease will have a mutation in the Janus Kinase (JAK) 2 gene, such as JAK2V617F mutations and JAK exon 12 mutations. This article will review the biology of the disease, as well as diagnosis. We will also discuss different treatment options available. Finally, we will review the long-term risks of the disease, such as transformation to myelofibrosis and acute leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994;47(2):89–93. https://doi.org/10.1002/ajh.2830470205.

    Article  PubMed  Google Scholar 

  2. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008;83(5):359–62. https://doi.org/10.1002/ajh.21129.

    Article  PubMed  Google Scholar 

  3. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595–600. https://doi.org/10.3109/10428194.2013.813500.

    Article  PubMed  Google Scholar 

  4. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Original article. Leukemia. 2013;27(9):1874–81. https://doi.org/10.1038/leu.2013.163.

    Article  PubMed  PubMed Central  Google Scholar 

  5. James C, Ugo V, Le Couedic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8. https://doi.org/10.1038/nature03546. http://www.nature.com/nature/journal/v434/n7037/suppinfo/nature03546_S1.html.

    Article  PubMed  Google Scholar 

  6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90. https://doi.org/10.1056/NEJMoa051113.

    Article  PubMed  Google Scholar 

  7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. https://doi.org/10.1016/j.ccr.2005.03.023.

    Article  PubMed  Google Scholar 

  8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61. https://doi.org/10.1016/S0140-6736(05)71142-9.

    Article  PubMed  Google Scholar 

  9. Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–10. https://doi.org/10.1182/blood-2013-09-527903.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664–70. https://doi.org/10.1182/blood-2004-09-3426.

    Article  PubMed  Google Scholar 

  11. Ferrari A, Carobbio A, Masciulli A, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019;104(12):2391–9. https://doi.org/10.3324/haematol.2019.221234.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lee G, Arcasoy MO. The clinical and laboratory evaluation of the patient with erythrocytosis. Eur J Intern Med. 2015;26(5):297–302. https://doi.org/10.1016/j.ejim.2015.03.007.

    Article  PubMed  Google Scholar 

  13. Malyszko J, Oberbauer R, Watschinger B. Anemia and erythrocytosis in patients after kidney transplantation. Transpl Int. 2012;25(10):1013–23. https://doi.org/10.1111/j.1432-2277.2012.01513.x.

    Article  PubMed  Google Scholar 

  14. Roskoski R. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784–803. https://doi.org/10.1016/j.phrs.2016.07.038.

    Article  PubMed  Google Scholar 

  15. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544.

    Article  PubMed  Google Scholar 

  16. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89(1):52–4. https://doi.org/10.1002/ajh.23585.

    Article  PubMed  Google Scholar 

  17. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32. https://doi.org/10.1200/jco.2005.07.062.

    Article  PubMed  Google Scholar 

  18. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. https://doi.org/10.1056/NEJMoa1208500.

    Article  PubMed  Google Scholar 

  19. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–81. https://doi.org/10.1182/blood-2013-01-478891.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Network NCC. Myeloproliferative neoplasm, version 3/2019. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf.

  21. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17–23.

    PubMed  Google Scholar 

  22. Kiladjian J-J, Chevret S, Dosquet C, Chomienne C, Rain J-D. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907–13. https://doi.org/10.1200/jco.2011.36.0792.

    Article  PubMed  Google Scholar 

  23. Talpaz M, Kantarjian H, Kurzrock R, Trujillo J, Gutterman J. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114(7):532–8. https://doi.org/10.7326/0003-4819-114-7-532.

    Article  PubMed  Google Scholar 

  24. Silver R. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988;332(8607):403. https://doi.org/10.1016/S0140-6736(88)92881-4.

    Article  Google Scholar 

  25. Kiladjian J-J, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065–72. https://doi.org/10.1182/blood-2008-03-143537.

    Article  PubMed  Google Scholar 

  26. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418–24. https://doi.org/10.1200/jco.2009.23.6075.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498–509. https://doi.org/10.1182/blood.2019000428.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175–84. https://doi.org/10.1016/s2352-3026(20)30373-2.

    Article  PubMed  Google Scholar 

  29. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–35. https://doi.org/10.1056/NEJMoa1409002.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs). Cancer. 2007;109(1):68–76. https://doi.org/10.1002/cncr.22365.

    Article  PubMed  Google Scholar 

  31. Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8. https://doi.org/10.1182/blood-2011-01-328955.

    Article  PubMed  Google Scholar 

  32. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form Total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103. https://doi.org/10.1200/jco.2012.42.3863.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Grunwald MR, Burke JM, Kuter DJ, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2019;19(9):579–584.e1. https://doi.org/10.1016/j.clml.2019.06.001.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Mesa R, Verstovsek S, Kiladjian J-J, et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016;97(2):192–200. https://doi.org/10.1111/ejh.12707.

    Article  PubMed  Google Scholar 

  35. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24. https://doi.org/10.1056/NEJMoa035572.

    Article  PubMed  Google Scholar 

  36. Hultcrantz M, Björkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms. Ann Intern Med. 2018;168(5):317–25. https://doi.org/10.7326/M17-0028.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560–1. https://doi.org/10.1182/blood-2015-04-638593.

    Article  PubMed  Google Scholar 

  38. Cerquozzi S, Barraco D, Lasho T, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7(12):662. https://doi.org/10.1038/s41408-017-0035-6.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hamulyák EN, Daams JG, Leebeek FWG, et al. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Adv. 2021;5(1):113–21. https://doi.org/10.1182/bloodadvances.2020003628.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(17):2410–5. https://doi.org/10.1200/JCO.2011.34.7542.

    Article  Google Scholar 

  41. Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291–302. https://doi.org/10.1111/bjh.16380.

    Article  PubMed  Google Scholar 

  42. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21–30. https://doi.org/10.1182/bloodadvances.2016000216.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887–4897. Blood Adv 2020; 4(22): 5651–5651. doi:https://doi.org/10.1182/bloodadvances.2020003711.

  44. Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera. Cancer. 2005;104(5):1032–6. https://doi.org/10.1002/cncr.21297.

    Article  PubMed  Google Scholar 

  45. Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015;39(9):950–6. https://doi.org/10.1016/j.leukres.2015.06.001.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA

    Jeanne Palmer

  2. President, Atrium Health Levine Cancer, Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC, USA

    Ruben Mesa

Authors
  1. Jeanne Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruben Mesa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeanne Palmer .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Palmer, J., Mesa, R. (2023). Treatment Algorithm for Polycythemia Vera. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_37

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_37

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation